Gum Inflammation Risk and Your Genetics

Written by Scott Peeples, BS Biomedical Sciences · ExomeDNA Founder Reviewed by ExomeDNA Editorial Process Last reviewed: May 26, 2026

IL-1β in gingival crevicular fluid is a direct biomarker of periodontal inflammation — the immune activity in the tissue surrounding teeth that, when dysregulated, drives gum disease progression and tooth loss. IL1B and IL37, both members of the interleukin-1 cytokine family on chromosome 2, are the top-ranked genetic signals for elevated gingival IL-1β levels in a genome-wide study that linked inherited cytokine biology to clinical periodontal outcomes.^[1] Below: how inherited variation in the IL-1 cytokine cluster shapes gum inflammation, and what population research reveals about the genetics of periodontal health.

What is gum inflammation and IL-1 beta?

The gingival sulcus — the shallow groove between tooth and gum tissue — is continuously bathed in gingival crevicular fluid (GCF), a serum-derived fluid that reflects the inflammatory status of the surrounding periodontal tissue. GCF functions as a liquid biopsy of the local gingival immune environment: when periodontal inflammation is active, pro-inflammatory cytokines including interleukin-1β (IL-1β) accumulate in the fluid at concentrations that correlate with disease severity.

IL-1β is the dominant inflammatory cytokine in periodontal tissue immune responses. It is produced primarily by macrophages and monocytes activating in response to bacterial signals from dental plaque. IL-1β recruits additional immune cells, promotes bone-resorbing osteoclast activity, and drives the tissue-destructive cascade that, when persistent, results in clinical periodontitis — including alveolar bone loss, periodontal pocket deepening, and eventual tooth loss. GCF IL-1β level is both a marker of current gingival inflammation and a predictor of future periodontal disease progression.

Genetically elevated susceptibility to high GCF IL-1β does not arise from making more IL-1β alone — it also arises from reduced capacity to suppress IL-1β. The IL-1 superfamily includes both pro-inflammatory members (IL-1β, IL-36 cytokines) and anti-inflammatory members (IL-37, IL-1RN/IL-1 receptor antagonist). Variants that impair the anti-inflammatory brake allow IL-1β responses to escalate in the periodontal tissue without adequate counter-regulation.

The genetics of gum inflammation

The genetic architecture of gingival IL-1β elevation is anchored in the IL-1 cytokine superfamily cluster on chromosome 2q14 — a genomic region encoding both pro-inflammatory and anti-inflammatory members of the IL-1 family. IL1B and IL37 are the highest-confidence genetic signals identified in fine-mapped genome-wide data for this trait.^[1]

A variant in the IL37 locus reached genome-wide significance at p = 3.3×10⁻²² for elevated IL-1β in gingival crevicular fluid in 4,910 European-American individuals, replicated in 4,927 German and Dutch adults (Offenbacher et al. 2018, Nature Communications) — the first genome-wide significant finding linking cytokine genetics to periodontal inflammation severity.^[1]

IL37 encodes interleukin-37 — a natural anti-inflammatory cytokine in the IL-1 superfamily that broadly suppresses innate immune activation. IL-37 inhibits IL-1β signaling, reduces NF-κB activation, and attenuates pro-inflammatory cytokine cascades. In periodontal tissue, IL-37 functions as a brake on inflammation: when bacterial signals activate IL-1β production, IL-37 production normally rises in parallel to limit the response. Variants near IL37 that impair IL-37 protein production or caspase-1-mediated processing of the IL-37 precursor weaken this brake, allowing IL-1β responses to escalate without adequate counter-regulation — which is why these variants associate with higher GCF IL-1β and more severe periodontitis.

The IL37 locus variant associated with elevated gingival IL-1β also associated with an odds ratio of 1.50 for severe chronic periodontitis and a relative risk of 1.33 for losing three or more teeth over 10 years — establishing that inherited variation in the anti-inflammatory cytokine balance at this locus translates into clinically meaningful differences in periodontal disease outcomes.^[1]

IL1B (rank 1) encodes interleukin-1 beta itself — the cytokine being directly measured. Variants affecting IL1B expression or processing shift the baseline availability of IL-1β in periodontal tissue. IL1B is the founding member of the IL-1 superfamily and the primary pro-inflammatory driver in innate immune responses across many tissues. IL36G (IL-36 gamma) is another pro-inflammatory IL-1 family member expressed in gingival keratinocytes and mucosal epithelia, acting in concert with IL-1β in mucosal immunity. The broader filtered gene cluster for this trait — including IL1A, IL1F10, IL1RN, IL36A, and IL36B — spans the full IL-1 cytokine region on chromosome 2, reflecting how genetic variation across the entire pro- and anti-inflammatory cytokine balance of this locus shapes periodontal inflammation susceptibility.

What the research says

Research base: Moderate. The genetic architecture of gingival IL-1β elevation is supported by the genome-wide association study of IL-1β in gingival crevicular fluid by Offenbacher et al. (2018, Nature Communications), with 4,910 European-American participants in discovery and 4,927 German and Dutch participants in replication.^[1] The IL37 locus reached genome-wide significance and was replicated, with functional studies confirming the mechanism. Moderate confidence reflects the adequate discovery and replication sample sizes for this specialized phenotype, the restriction to European ancestry, and the use of GCF cytokine measurement rather than clinical periodontal disease classification as the primary phenotype — which, while more mechanistically precise, limits direct comparison to larger clinical GWAS. See our methodology page for how we evaluate and apply genetic evidence in your ExomeDNA profile.

How gum inflammation genetics affects health

The gingival tissue is highly vascularized, and chronic inflammation at this site — driven by IL-1β dysregulation — allows periodontal bacteria and inflammatory mediators to enter systemic circulation through the blood-rich sulcular epithelium. Periodontal disease is bidirectionally associated with cardiovascular disease, type 2 diabetes, adverse pregnancy outcomes, and respiratory conditions through this systemic inflammatory pathway.

The IL-1β cascade is mechanistically linked to each of these systemic associations: elevated IL-1β promotes endothelial activation and vascular inflammation (relevant to cardiovascular disease), drives insulin resistance through cytokine-mediated disruption of insulin signaling (relevant to type 2 diabetes), and triggers systemic acute-phase responses. A higher genetic risk score for gum inflammation reflects greater inherited susceptibility to elevated gingival IL-1β and the local and systemic inflammatory consequences it drives.

Critically, this is a substantially modifiable risk: consistent oral hygiene and professional dental care reduce the bacterial load that triggers IL-1β production, lowering gingival inflammation regardless of inherited cytokine biology. Genetic susceptibility raises the stakes for oral care adherence; it does not make periodontal health unmanageable.

Working with your gum inflammation result

What research suggests about managing gingival inflammation

• Consistent oral hygiene: brushing twice daily with fluoride toothpaste and daily flossing removes the dental biofilm (plaque) that triggers IL-1β production — this is the most impactful intervention for anyone with elevated periodontal inflammation susceptibility.^[1]
• Professional dental cleaning: removes subgingival calculus that harbors bacteria below the gum line, essential for individuals with deeper periodontal pockets or active inflammation; more frequent professional care (3–4 times annually) may benefit those with genetic inflammatory susceptibility.
• Tobacco avoidance: smoking is the strongest behavioral risk factor for periodontitis — it suppresses gingival immune defense, impairs healing, and exacerbates IL-1β-driven tissue destruction.
• Blood sugar management: elevated blood glucose worsens periodontal inflammation through advanced glycation end-product formation and immune dysregulation; diabetes and periodontitis have well-documented bidirectional effects.
• Anti-inflammatory nutrition: diets rich in omega-3 fatty acids (fatty fish, flaxseed) and antioxidants (fruits, vegetables) may reduce systemic and local inflammatory cytokine levels; some evidence supports omega-3 supplementation improving periodontal outcomes.
• Early intervention: the transition from gingivitis (reversible inflammation) to periodontitis (irreversible bone loss) is shaped by the persistence of inflammation — individuals with inherited IL-1β elevation benefit from catching inflammation early, when intervention can prevent permanent structural damage.

Related traits and genes

Gum inflammation genetics connects directly to Periodontal Disease Risk, which captures the broader clinical disease endpoint that elevated gingival IL-1β predicts. C-Reactive Protein Levels reflects the systemic acute-phase inflammatory response that runs in parallel with local gingival IL-1β elevation. Cardiovascular Disease Risk connects through the bidirectional periodontal-vascular biology, with chronic gingival IL-1β contributing to systemic endothelial inflammation.

Within immunity, Rheumatoid Arthritis Risk shares IL-1 pathway genetics — IL-1 receptor antagonist (IL1RN), present in the IL-1 cluster for this trait, is a therapeutic target in RA, reflecting the shared IL-1β biology between joint and gingival inflammation. Type 2 Diabetes Risk reflects the bidirectional relationship between periodontal IL-1β dysregulation and systemic insulin resistance. IL-6 Levels represents the downstream systemic cytokine cascade that IL-1β initiates.

Frequently asked questions

What is IL-1β and why is it measured in gingival crevicular fluid?

IL-1β (encoded by IL1B) is a potent pro-inflammatory cytokine produced by macrophages and monocytes in response to bacterial signals. In the gingival sulcus — the groove between tooth and gum — bacteria from dental plaque trigger IL-1β release from immune cells in the periodontal tissue. Gingival crevicular fluid, which seeps from this sulcus, accumulates this IL-1β in concentrations that directly reflect local immune activation. GCF IL-1β is one of the most validated biomarkers of current periodontal inflammation severity and predictor of future disease progression.

How do IL37 variants cause higher gum inflammation?

IL-37 is a natural anti-inflammatory cytokine that normally suppresses IL-1β signaling and other innate immune cascades — it acts as a brake on the inflammatory response. Variants near IL37 that impair IL-37 protein production or caspase-1-mediated processing weaken this brake, allowing IL-1β production in response to bacterial signals to escalate without adequate counter-regulation. The Offenbacher 2018 study confirmed that these variants impair IL-37 functional production and associate with higher GCF IL-1β, more severe periodontitis, and greater tooth loss over 10 years.

Is gum inflammation risk purely genetic or does behavior matter?

Behavior matters substantially. The genetic susceptibility captured here reflects inherited capacity for IL-1β dysregulation — but IL-1β production requires a trigger, which is bacterial plaque. Consistent oral hygiene, professional dental cleaning, and tobacco avoidance reduce the bacterial load that activates the IL-1β cascade, substantially modifying the expression of genetic susceptibility. Many individuals with high genetic susceptibility maintain healthy periodontal tissue through excellent oral hygiene; many with low genetic susceptibility develop periodontitis through poor oral care. Genetics raises the stakes; behavior determines the outcome.

Does gum inflammation affect the rest of the body?

Yes. Chronic periodontal inflammation allows bacteria and inflammatory cytokines including IL-1β to enter systemic circulation through the highly vascularized gingival tissue. This systemic spill is mechanistically linked to vascular inflammation (relevant to cardiovascular disease), insulin resistance (relevant to type 2 diabetes), and adverse pregnancy outcomes. Periodontal disease is bidirectionally associated with cardiovascular disease and type 2 diabetes in population studies — both conditions worsen periodontal outcomes, and periodontal disease worsens both systemic conditions in parallel.

What is the difference between IL1B and IL37 in this genetic landscape?

IL1B encodes the pro-inflammatory cytokine IL-1β itself — the molecule being measured in GCF. Variants near IL1B that increase expression or alter processing of IL-1β directly shift its baseline availability in periodontal tissue. IL37 encodes IL-37, an anti-inflammatory cytokine that suppresses IL-1β and other pro-inflammatory signals — variants impairing IL-37 remove the natural brake on the IL-1β response. Both genes sit in the same IL-1 superfamily cluster on chromosome 2, reflecting how the genetic balance between pro- and anti-inflammatory cytokine biology at this locus determines inherited periodontal inflammation susceptibility.

References

1. Offenbacher S, et al. (2018). GWAS for Interleukin-1β levels in gingival crevicular fluid identifies IL37 variants in periodontal inflammation. Nat Commun. PMID: 30206230. DOI: 10.1038/s41467-018-05940-9.

Data sources:

• GWAS Catalog (NHGRI-EBI, accessed 2026-05-26)
• Open Targets Platform (CC0 1.0, accessed 2026-05-26)
• ClinVar (NCBI, accessed 2026-05-26) — entries at ≥2-star review status
• ClinGen Gene-Disease Validity (CC0 1.0, accessed 2026-05-26)

This page is published by the ExomeDNA Research Team. Last reviewed: 2026-05-26.